OmniAb, Inc.
OmniAb, Inc. licenses antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The company’s platform combines engineered transgenic animals, computational design, and screening tools to generate and optimize antibody and other target-binding protein candidates for therapeutic development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaLicenses and access agreements for use of the OmniAb discovery platform.
Research services supporting partner antibody discovery and optimization programs.
Upfront and contingent payments tied to partner program progress and agreements.
Instruments and related consumables sold for discovery workflows.
Payments tied to commercial sales of partner-developed products.
Tuotteet
Raportoitu · osuus liikevaihdosta- License and Milestone Revenue52,3 %
- Services38,9 %
- Royalty4,7 %
- X Ploration Revenue4,0 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
OmniAb sells primarily to pharmaceutical and biotechnology companies that need antibody discovery capabilities for therapeutic pipelines. It also serves academic institutions and research organizations that use the platform for discovery research, and its royalty stream depends on partners that successfully advance and commercialize OmniAb-derived programs.
Buy platform access, discovery services, and milestone-based programs to source therapeutic antibodies.
Use OmniAb to accelerate early-stage biologic discovery and candidate optimization.
Access the technology for research discovery and target-binding protein work.
Generate royalties when partner-developed OmniAb-derived products sell in market.
Strategia
OmniAb’s strategy centers on expanding adoption of its antibody discovery platform and converting partner programs into milestones, services, and royalties. The company also emphasizes differentiated technology breadth, including engineered animals, computational tools, and screening methods, to support more complex biologic modalities and deepen partner relationships.
A larger installed base increases recurring access, service, milestone, and royalty opportunities.
Later-stage progression increases milestone recognition and future royalty potential.
Scientific performance and customization drive partner adoption in a competitive discovery market.
Supporting bispecifics, ADCs, CAR-T, and radiotherapeutics widens the addressable market.
Maantiede
OmniAb is a U.S.-based company with operations and partners serving a global pharmaceutical market. The filings do not provide a country revenue split, but they do indicate royalty exposure to partner product sales in China, showing that commercial outcomes in that market can affect results.
Riskit
OmniAb depends on partners to advance discovery and commercialization, so revenue can be affected by program timing, partner execution, and regulatory outcomes outside its control. The business also faces technology adoption risk, cybersecurity/data protection risk, and exposure to geographic demand shifts such as lower partner sales in China.
- Partner development and commercialization dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Milestones, approvals, and royalties depend on partner execution rather than OmniAb control.
Kohdistuu: Discovery programs and royalty streams
- Platform adoption and technology competitionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Customers can choose alternative antibody discovery methods and platforms.
Kohdistuu: New licenses and renewals
- Cybersecurity and data protectionVaikutus: KeskitasoTodennäköisyys: Matala
The company stores sensitive research, IP, and partner data across internal and cloud systems.
Kohdistuu - Capital access and funding needsVaikutus: KeskitasoTodennäköisyys: Matala
If operating cash is insufficient, the company may need external financing.
Kohdistuu: Liquidity and growth investment
- China market exposureVaikutus: Keskitaso
Royalty revenue was affected by lower partner product sales in China.
Kohdistuu: Partner commercialization and royalty receipts
Kirjanpito
Harkinnanvaraiset erätDifferent contract components are recognized at different times, creating quarter-to-quarter volatility.
Vaikutus: Reported revenue can shift materially with partner milestones and sales reports
Royalty revenue depends on partner-provided sales data and commercial timing.
Vaikutus: Revenue may lag underlying product sales and vary by geography
Management must compare carrying value to estimated fair value using forecasts and market inputs.
Vaikutus: Could create non-cash charges if assumptions weaken
Acquired technology and related assets require ongoing recoverability assessments.
Vaikutus: Could affect earnings if expected benefits decline
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Xencor Inc
XNCR · Pharmaceutical Preparations
iBio, Inc.
IBIO · Pharmaceutical Preparations
Omnicell, Inc
OMCL · Electronic Computers
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
REGENXBIO Inc.
RGNX · Biological Products, (No Diagnostic Substances)
Rallybio Corp
RLYB · Pharmaceutical Preparations
Rallybio Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with significant unmet medical need.
Päivitetty: 24.9.2026